Alzinova Announces First Quarter 2024 Earnings

Alzinov (STO:ALZ) Q1 2024 results

Key financial results

Revenue: 2.85 million kr (down 39% compared to Q1 2023).
Net loss: 4.96 million kr (loss increased by 16% compared to the first quarter of 2023).

OM:ALZ Earnings and Revenue Growth, May 30, 2024

All data shown in the chart above is for a 12-month (TTM) period.

Alzinov’s earnings statistics

Looking ahead, revenues are expected to decline by an average of 62% per year over the next 3 years, while revenues in the biotech industry in Sweden are expected to grow by 16%.

Efficiency The Swedish biotechnology industry.

The company’s shares increased by 32% compared to a week ago.

Risk assessment

Don’t forget that there may still be risks. For example, we identified 5 warning signs for Alzinov (3 should not be ignored) you should know about.

Pricing is complex, but we help simplify it.

Find out whether Alzinova is potentially overvalued or undervalued by checking out our comprehensive analysis, which covers fair value estimates, risks and warnings, dividends, insider transactions and financial condition.

View free analysis

Have an opinion on this article? Worried about content? contact with us directly. Alternatively, email the editorial team (at) simplywallst.com.

This article by Simply Wall St is of a general nature. We comment based on historical data and analyst forecasts, using only an unbiased methodology, and our articles are not intended to provide financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide long-term, focused analysis based on fundamental data. Please note that our analysis may not reflect the latest price-sensitive company announcements or qualitative content. Simply Wall St has no position in any of the stocks mentioned.